<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of a 36-year old woman with HER2-positive early <z:hpo ids='HP_0003002'>breast cancer</z:hpo> treated with adjuvant trastuzumab left ventricle dysfunction and <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> in <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> mechanism is presented </plain></SENT>
<SENT sid="1" pm="."><plain>After having been successfully resuscitated, trastuzumab therapy was withheld, pharmacotherapy (beta-blocker, ACE-I) implemented and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> was implanted </plain></SENT>
<SENT sid="2" pm="."><plain>Echocardiography performed 6 months later, revealed <z:mpath ids='MPATH_458'>normal</z:mpath> systolic function of the left ventricle </plain></SENT>
<SENT sid="3" pm="."><plain>The patient died despite further oncologic treatment due to progression of the disease </plain></SENT>
<SENT sid="4" pm="."><plain>The authors discuss the approach to this dramatic but lone cardiac side effect of trastuzumab treatment </plain></SENT>
</text></document>